A Study to Evaluate the Efficacy and Safety of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria（PNH）

Exclusion Criteria

• •1. Hereditary or acquired complement deficiency;
• •2. Active primary or secondary immunodeficiency;
• •3. History of splenectomy, bone marrow/ hematopoietic stem cell or solid organ transplants;
• •4. History of recurrent invasive infections caused by encapsulated organisms( e.g. meningococcus or pneumococcus) or Mycobacterium tuberculosis;
• •5. Patients with laboratory evidence of bone marrow failure (reticulocytes \< 100x10\^9/L, or platelets \< 30x10\^9/L or neutrophils \< 0.5x10\^9/L) ;
• •6. Active systemic infection within 2 weeks prior to study drug administration;
• •7. History of serious comorbidities that have been determined to be unsuitable for participation in the study.
• •8. Pregnant or Lactating women.